Stock analysts at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reduced their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th.
View Our Latest Stock Report on Minerva Neurosciences
Minerva Neurosciences Stock Performance
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). Research analysts predict that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
See Also
- Five stocks we like better than Minerva Neurosciences
- Using the MarketBeat Dividend Yield Calculator
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- When to Sell a Stock for Profit or Loss
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Health Care Stocks Explained: Why You Might Want to Invest
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.